UmbriaExplore our travel guides. Share your stories, tips and questions on Reddit.
Fast movers • Alerts • Momentum
10% OFF with SAVE10
Charts • Watchlists • Multi-broker tools
Built for active traders
Biotech catalyst, news and analysis PDUFA tracker
Biotech catalyst, news and analysis PDUFA tracker
Cingulate remains focused on the manufacturing work needed to resubmit the CTx-1301 NDA after the June 1, 2026 Complete Response Letter. Its September 17 communication repeated the plan to resubmit as promptly as practicable without a date. June 30 cash was $28.4 million, with management forecasting funding into mid-2027 and retaining going-concern doubt. Clinical publications support the development record but do not resolve manufacturing requirements.
Get every Merlintrader report in real time on Telegram: join @merlintraderpub_com.
The Form 10-Q of August 13, 2026 states only that Cingulate intends to resubmit as promptly as practicable. Until a resubmission is announced and accepted, there is no action date and the file has no dated catalyst. The next periodic financial disclosure is the third-quarter 2026 report, whose date the company had not announced as of October 4, 2026.
A development-stage therapeutic company is repriced by single events: a resubmission acceptance, an action date, an approval or another Complete Response Letter. Between those events the financial statements describe the runway rather than the value: $28.4 million of cash at June 30, 2026 against $12.8 million of operating cash use in the first half, with substantial-doubt language retained in the Form 10-Q of August 13, 2026.
The company describes the CRL as CMC-related, without current clinical safety or efficacy concerns. The pediatric publication supports two tested doses at the adjusted threshold, and the August pharmacokinetic publication adds detail on the release profile. June cash and the company’s mid-2027 funding forecast provide resources for remediation, while approval remains unconfirmed.
The publicly described manufacturing work has no announced completion or resubmission date. First-half operating cash use was $12.8 million and substantial-doubt language remains. The current Avondale note, manufacturing commitments and commercial preparation compete for cash. A near doubling of common shares since December 2025 shows why progress at the company can coexist with dilution for holders.
Cingulate held $28.4 million of cash and $21.6 million of working capital at June 30, 2026. Q2 net loss was $5.9 million and first-half operating cash use was $12.8 million. The $5.1 million Avondale note was classified as current. Management forecast funding into mid-2027, but retained substantial doubt about continuing as a going concern. The balances are historical and do not represent cash available today. Q2 Form 10-Q.
CTx-1301 seeks to improve delivery of an established ADHD stimulant through three timed releases. The evidence includes a small adult study that missed its primary statistical threshold and a prematurely closed pediatric study in which two of three doses met the adjusted threshold. The disclosed regulatory obstacle concerns manufacturing; resolving it requires a complete response and FDA review, not another description of the release mechanism. Funding, share issuance and eventual commercial access therefore remain as important to the investment analysis as supportive clinical findings.
The CEO and Chief Commercial Officer were scheduled for September 22 sessions on commercial launch models. The release reiterated ongoing CMC work and an intention to resubmit promptly, with no assurance of timing or approval. The summit date has passed and is not a future regulatory catalyst.
The Form 10-Q for the quarter ended June 30, 2026 reports $28.4 million of cash and equivalents against $11.0 million at December 31, 2025, working capital of $21.6 million, a net loss of $5.9 million for the quarter and $15.2 million for the six months, and $12.8 million of cash used in operations over the half. The cover shows 14,541,826 shares at August 12, 2026. Management states the cash is sufficient into mid-2027, retains substantial-doubt language and says only that it intends to resubmit the NDA as promptly as practicable, with no assurance on timing, acceptance or approval.
The open-access paper in the Journal of Child and Adolescent Psychopharmacology confirms dose-related ADHD-RS-5 improvement and no new safety signal. The 25 mg and 37.5 mg groups met the multiplicity-adjusted threshold of p<0.017; the 18.75 mg group reported p=0.018 and narrowly missed it. The authors describe the findings as preliminary because 103 of the planned 385 participants were enrolled. It supports the clinical side of the NDA; it does not answer the manufacturing questions in the CRL.
Cingulate announced that the FDA issued a Complete Response Letter on June 1, 2026 for the CTx-1301 NDA, citing chemistry, manufacturing and controls items. The company said the letter did not identify clinical efficacy or safety deficiencies and that it intended to work with the FDA toward a resubmission. Four months later no resubmission, classification (Class 1 or Class 2) or new action date had been announced.
The company announced publication of a randomized crossover bioavailability study comparing trimodal CTx-1301 with a bimodal dexmethylphenidate formulation in adults with ADHD. Its reported early and late exposure profile supports the delivery rationale; pharmacokinetic exposure alone does not prove comparative symptom control or resolve the CRL.
The full deep dive has the answer’s building blocks: cash, dilution, catalysts and risks, every figure sourced.
Free. No signup. You decide, we don’t recommend.
| Catalyst | Status | Why it matters | What would be constructive |
|---|---|---|---|
| Detailed CMC remediation update | Awaited | Defines whether the CRL is narrow documentation work or a deeper manufacturing program. | Specific completed tasks, validation evidence and a credible submission window. |
| NDA resubmission | Not announced | Starts the next formal FDA review cycle. | A complete response addressing every deficiency, not a partial update. |
| FDA filing/classification | Future | Class 1 generally implies a shorter review goal; Class 2 implies a longer review and more burn. | Acceptance without another unexpected deficiency and a clearly stated classification. |
| New action date | None | Restores a hard regulatory calendar anchor. | A formally communicated target date tied to the accepted resubmission. |
| Manufacturing inspection status | Unresolved publicly | The February 2026 pre-approval inspection produced three Form 483 observations at the CDMO: two related to the facility and one specific to CTx-1301. The CDMO is preparing responses, and the FDA may re-inspect on resubmission. | Evidence that both the facility observations and the product-specific observation have been remediated to FDA satisfaction. |
| Q2 financial report | Reported August 13, 2026 | Showed $28.4 million of cash at June 30, 2026, $12.8 million of six-month operating cash use and a runway management now states as into mid 2027, while the filing retains substantial doubt about going-concern status. | The print carried no resubmission date, so the constructive follow-up is dated regulatory progress alongside the same financing transparency and a rephasing of launch spending. |
| Prasco distribution agreement | Signed | The exclusive services agreement signed July 21, 2026 supplies integrated third-party logistics and distribution designed to support national availability across major wholesalers plus direct distribution to approximately 19,000 independent and smaller regional pharmacy accounts under Prasco’s UNLIMIT program. | Distribution readiness assembled without a large fixed cost base, and timed to a potential approval rather than committed far ahead of one. |
| Approval and label | Uncertain | Would move CING from a development company toward commercial execution. | Approval across the intended age range and dosage strengths without commercially restrictive surprises. |
| Launch and payer access | Post-approval | Approval alone does not prove pricing, reimbursement, physician adoption or profitable demand. | Disciplined field build-out, broad access and evidence that the duration profile changes prescribing behavior. |
The analysis rests on Cingulate’s CRL being described as CMC-related, without current clinical safety or efficacy concerns, while the resubmission has no announced date. The following developments would materially change that reading.
These are observations that would weaken the interpretation, not forecasts of inevitable events.
Cingulate Therapeutics was formed in November 2012. The public holding company was created in 2021, acquired the operating business through a reorganization merger, and completed its initial public offering in December of that year. The founding concept was not to discover an entirely new stimulant. It was to improve how established ADHD drugs are delivered across a patient’s active day.
The company licensed controlled-release barrier-layer technology from BDD Pharma. Under that agreement, Cingulate obtained exclusive rights within defined fields to develop products capable of delivering three distinct doses of dexmethylphenidate, dextroamphetamine or related stimulant compounds. The economic obligation is not trivial but is manageable relative to a successful branded product: the 2025 Form 10-K described a final $250,000 milestone upon FDA approval of CTx-1301 and low- to mid-single-digit royalties on applicable net sales or receipts.
Cingulate’s corporate life has repeatedly alternated between scientific progress and financing stress. The company has never generated product revenue. It used private capital before the IPO, public offerings, at-the-market sales, equity purchase facilities, debt, warrant inducements and private placements to fund development. It also completed a 1-for-20 reverse stock split in November 2023 and a 1-for-12 reverse split in August 2024. Those actions preserved the Nasdaq listing but are essential context when looking at long-term price charts: historical per-share prices are mechanically inflated by cumulative split adjustments and do not represent comparable economic value.
By 2025, the company had moved beyond early pharmacokinetic proof and into a filing campaign. Safety updates, a pre-NDA meeting, a high-dose food-effect study and pediatric efficacy data were followed by an FDA user-fee waiver and the July 31 NDA submission. Cingulate simultaneously built the commercial and manufacturing infrastructure it believed it would need after approval. This included an exclusive manufacturing relationship with Bend Bioscience, commercial services with Indegene and an arrangement with IQVIA for field sales and national account management.
The same manufacturing strategy that signaled launch readiness became the central regulatory weakness. In February 2026, the FDA conducted a pre-approval inspection of Bend’s Gainesville, Georgia facility. The CDMO received a Form 483 with three observations: two related to the facility and one specific to CTx-1301. Cingulate had already disclosed multiple FDA information requests, primarily related to CMC. The CRL therefore did not emerge from nowhere. It crystallized a risk visible in the company’s own March filing.
CTx-1301 is a film-coated, multi-core tablet containing dexmethylphenidate hydrochloride. The company expects eight dosage strengths ranging from 6.25 mg to 50 mg. Its differentiation is the release architecture. The tablet combines an immediate-release component with two delayed-release cores surrounded by erosion barrier layers. Those barriers are engineered to prevent premature release and then erode at predefined times.
The intended dexmethylphenidate release ratio is 35% initially, 45% in the second pulse and 20% in the third pulse. The late 20% pulse is the “built-in booster.” Rather than asking a patient to carry and take a separate short-acting stimulant later in the day, Cingulate wants one morning tablet to supply an early effect, reinforce exposure as the first dose declines and extend useful coverage into the late active day. The company also argues that a controlled descent in plasma levels may reduce the abrupt wear-off, rebound or crash some patients experience.
This is a credible product-design hypothesis, but it creates a high manufacturing bar. Each layer, core, dissolution profile and dose strength must be produced consistently. The regulatory question is not simply whether dexmethylphenidate works—it is already a well-known stimulant—but whether this precise product can be manufactured reproducibly, remain stable, meet specifications and deliver the intended profile across commercial batches.
The platform itself is partly dependent on licensed BDD Pharma technology, including the Oralogik erosion barrier formulation. Cingulate owns and is building additional intellectual property around its specific products and release profiles. The June 2026 U.S. patent is therefore valuable: it protects key aspects of the CTx-1301 formulation and method of use through December 2042. Still, a patent protects exclusivity; it does not validate manufacturing readiness, FDA approvability, reimbursement or market adoption.
In the 2020 comparative bioavailability study, Cingulate reported that adjusted geometric mean ratios for the primary exposure parameters were within the conventional 80%–125% range versus Focalin XR at tested high and low doses. That work created the scientific bridge to the reference listed drug. A later analysis also suggested that the three-pulse profile delivered the planned late-day exposure and that study-drug-related treatment-emergent adverse events were lower than with Focalin XR in that small program.
For a 505(b)(2) product, this bridge matters because the sponsor can rely in part on the FDA’s prior findings for the referenced drug while supplying data needed to support the formulation differences. It is not the same as filing a simple generic application. CTx-1301’s release pattern and proposed clinical use must still be adequately supported.
The adult laboratory-classroom study enrolled only 21 adults aged 18–55. Following dose optimization, participants were randomized to CTx-1301 or placebo. The primary PERMP comparison over the 16-hour assessment showed a trend toward statistical significance, with p=0.089, but did not meet the standard threshold. This is the most important limitation in the adult efficacy story and should never be hidden behind the company’s effect-size language.
The supportive results were better. Cingulate reported PERMP effect sizes ranging from 0.88 to 2.60, averaging 1.79; the treatment effect was 1.41 at 30 minutes and 0.98 at 16 hours. CGI-S improved by 1.2 points in the active arm versus no change on placebo, with p<0.001, and AISRS scores fell by 16.3 points. Only one mild treatment-emergent adverse event was reported in the active arm during the randomized period, versus three events in the placebo group.
The balanced interpretation is straightforward: the small adult study did not establish the primary endpoint statistically, but the application included the effect-size pattern, secondary measures, the 505(b)(2) bridge and broader clinical package. FDA acceptance for review does not establish that any individual dataset met an approval standard. The CRL, as summarized by Cingulate, did not reopen the efficacy question. That does not convert an underpowered primary-endpoint miss into a success; it means the disclosed approval obstacle is elsewhere.
The pediatric fixed-dose study enrolled 103 patients aged 6–17, versus an original plan for 385, after the FDA advised that further conduct of the pediatric studies was not required for the NDA. The July 2026 peer-reviewed paper reports mean ADHD-RS-5 reductions of 18.0, 17.8 and 22.0 points for the 18.75-mg, 25-mg and 37.5-mg groups, respectively, compared with an 8.1-point reduction on placebo. The model-based placebo-adjusted treatment differences were −8.81, −9.34 and −14.16 points.
The statistical interpretation requires precision. Cingulate’s July 30 release listed nominal p-values of 0.018, 0.011 and 0.001 and said all three dose groups improved versus placebo. However, the protocol used a stricter two-sided threshold of p<0.017 to account for the three comparisons. Under that prespecified rule, the 25-mg and 37.5-mg groups were statistically significant; the 18.75-mg group narrowly missed. The paper’s abstract and discussion state that statistical significance was not consistent across all doses.
The paper’s Results section reports exploratory post hoc effect sizes of 0.737, 0.782 and 1.185, with an overall effect size of 0.901. CGI-S improvement crossed the adjusted significance threshold only at 37.5 mg. Among the 83 participants with Week 5 CGI-I data, 57.1%, 57.1% and 68.4% in the active-dose groups were rated “much improved” or “very much improved,” versus 18.1% on placebo. A pooled post hoc analysis across all active doses was nominally significant, but pooled and post hoc results should not be confused with prespecified individual-dose testing.
The clinical signal is meaningful, especially given the small treatment groups, but the authors call the findings preliminary and say confirmation in a larger, adequately powered study is needed. They also note that common psychiatric comorbidities were excluded and that this trial did not measure time-of-day-specific efficacy; therefore, the company’s intended “entire active day” benefit cannot be directly inferred from this study alone.
During the five-week treatment period, at least one treatment-emergent adverse event was reported in 38.5% of placebo recipients, 50.0% of the 18.75-mg group, 34.6% of the 25-mg group and 68.0% of the 37.5-mg group. All TEAEs were mild or moderate. No serious TEAE or new safety signal was identified. The most frequently reported events across the study were decreased appetite at 14.6%, upper abdominal pain at 7.8% and headache at 6.8%.
Three participants discontinued treatment because of a TEAE: one placebo participant with joint stiffness, one 18.75-mg participant with headache and one 37.5-mg participant with chest pain. Each event was moderate, considered at least possibly treatment-related and resolved during follow-up. The highest dose therefore carried both the strongest efficacy signal and the highest TEAE incidence, reinforcing the practical importance of dose optimization if the product is approved.
Cingulate combined adult and pediatric safety information with food-effect work at the 25-mg and 50-mg strengths. The company reported no serious treatment-emergent adverse event, no TEAE leading to death and no clinically relevant overall TEAE trend in the analyzed studies. Both tested strengths supported dosing with or without food.
CTx-1301 remains a stimulant containing a Schedule II controlled substance. If approved, labeling would be expected to reflect class risks, including abuse, misuse, dependence and cardiovascular or psychiatric warnings where applicable. A favorable development-program safety summary does not make the product free of the established risks of dexmethylphenidate.
CMC covers the chemistry of the drug and excipients, the manufacturing process, analytical methods, specifications, stability, controls, facilities and evidence that commercial production can repeatedly make the product described in the application. For a simple tablet, this is already demanding. For a tablet whose purpose depends on three precisely timed releases, the relationship between process control and clinical behavior is even more direct.
A Form 483 is not itself a final agency determination that a company violated the law, and a CRL is not a permanent rejection. But both are serious. The FDA generally cannot approve a drug if it is not satisfied that manufacturing processes and facilities comply with current good manufacturing practice and can produce a consistent product. Cingulate must therefore close both the documentary and operational gap, not merely argue that the clinical data are good.
Possible workstreams include corrective and preventive actions at the facility, analytical-method validation, dissolution or release-specification work, process-performance qualification, updated batch records, stability packages and responses connecting any process change back to the submitted product. These are examples of what CMC remediation can involve, not a claim that every item appears in Cingulate’s confidential letter.
After a CRL, the FDA classifies a complete resubmission based on the scope of the response. A Class 1 response is generally associated with a two-month review goal; a Class 2 response is generally associated with a six-month goal. The review goal is measured from receipt of a complete resubmission; classification and any communicated action date must be confirmed separately. A progress statement does not start that review goal.
It is premature to assume Cingulate will receive Class 1 treatment. CMC responses that include substantial new data, validation or inspection work can support a Class 2 classification. Until the company submits and the FDA classifies the response, both timing paths remain scenarios rather than facts.
On July 20, Cingulate filed Form 4 reports for option awards granted on July 16. For CEO Shane Schaffer, 97,350 of the 295,000 options were structured so that vested options become exercisable only if the FDA approves CTx-1301 during 2027; the conditional portion terminates if approval does not occur during that year. Similar approval-contingent tranches were disclosed for other executives.
This design aligns some compensation with the regulatory outcome and indicates that a 2027 approval is important in the board’s incentive framework. It is not a promise that the resubmission will occur on a particular date, not confirmation of Class 1 or Class 2 status, and not evidence that the FDA has agreed to approval in 2027.
Cingulate does not own a commercial manufacturing facility. CoreRx, doing business as Bend Bioscience, is contracted to manufacture clinical, registration and—if approved—commercial CTx-1301 batches at its Gainesville, Georgia facility. Cingulate supplied equipment for a dedicated suite. The commercial supply agreement runs through August 2028, subject to its terms and possible renewal.
This outsourced model can limit fixed infrastructure costs, but it concentrates execution risk. If Bend’s facility, quality systems or product-specific process are not acceptable to the FDA, Cingulate cannot launch simply by having an approved clinical package. Moving to another manufacturer would not be a quick workaround; technology transfer, validation and regulatory amendments could add substantial time and expense.
Commercially, the company intends to avoid building a large standalone organization. Indegene can provide medical affairs, pricing, reimbursement, market access, operations and marketing under statements of work. IQVIA can support field sales and national accounts. Bryan Downey, appointed Chief Commercial Officer in November 2025, adds internal launch leadership.
That asset-light commercial plan is rational for a small company, but it does not eliminate launch costs or risk. Cingulate must fund inventory, distribution, rebates, payer contracting, medical education and sales execution before product cash flow can finance the operation. Every month of regulatory delay forces a choice between preserving readiness and conserving cash.
ADHD is a large, established market with tens of millions of diagnosed U.S. patients and approximately 100 million annual prescriptions according to Cingulate’s June release. Stimulants remain the most effective pharmacologic class for many patients. The opportunity is not based on creating a treatment category from nothing; it is based on persuading prescribers, payers and patients that a differentiated duration profile is worth using and reimbursing.
CTx-1301 would compete with generic immediate- and extended-release methylphenidate products, Focalin XR and generics, Concerta and generics, amphetamine products such as Adderall XR and Vyvanse, and newer branded formulations designed around onset, duration, convenience or abuse-deterrence. Generic availability creates price pressure. A novel delivery profile can earn a branded position, but payer access will depend on evidence, rebates and step-edit policies.
The product’s best commercial argument is practical: one morning tablet could replace an extended-release product plus an afternoon booster, simplify adherence and reduce the need to handle short-acting controlled medication at school or work. The hardest question is whether real-world patients and prescribers experience enough additional useful duration, with acceptable sleep, appetite and tolerability, to overcome formulary friction.
Aytu BioPharma remains a useful but imperfect peer. Aytu demonstrates that a small specialty-pharma company can operate an ADHD portfolio and generate meaningful revenue. It does not prove Cingulate’s launch economics. Aytu entered the comparison with commercial products and infrastructure; Cingulate is still pre-revenue and must cross manufacturing, approval, launch and financing hurdles in sequence.
| Program | Active ingredient | Target | Status and relevance |
|---|---|---|---|
| CTx-1301 | Dexmethylphenidate | ADHD, ages 6+ | Lead asset; NDA received a CMC-focused CRL. Almost all near-term company value depends on resubmission execution. |
| CTx-1302 | Dextroamphetamine | ADHD | Planned trimodal product using Dexedrine Spansule as the reference drug. Clinical plan depends on additional capital. |
| CTx-2103 | Buspirone | Anxiety disorders | Once-daily triple-release concept. Human formulation work showed the intended release pattern; further development needs capital. A $3 million non-dilutive grant supports part of the program. |
CTx-1302 uses the same platform logic with dextroamphetamine: 45% immediate release, 35% approximately three hours later and a 20% built-in booster around seven hours. The proposed program includes comparative bioavailability, food-effect and Phase 3 studies, but the company has clearly stated that initiation depends on funding.
CTx-2103 applies PTR to buspirone, an anxiety medicine commonly taken multiple times per day. A 10-subject formulation study tested delayed and triple-pulse tablets and produced pharmacokinetic and imaging information. The idea is commercially interesting because buspirone is non-benzodiazepine and widely used, but it remains far behind CTx-1301. Investors should not assign mature-product value to programs the company cannot advance without new capital.
| Metric | Q2 2026 / latest disclosed | Interpretation |
|---|---|---|
| Cash and equivalents | $28.4M at June 30, 2026 | Against $11.0M at December 31, 2025. The increase came from financing, not from the business. |
| Working capital | $21.6M at June 30, 2026 | Against $1.7M at year-end, an increase of $19.9M. The near-term liquidity squeeze visible at December 31 has eased. |
| Q2 net loss | $5.9M; $15.2M for the six months | Wider than the $5.0M second quarter of 2025 and the $8.8M first half of 2025. Loss per share nonetheless fell to $(0.45) from $(1.14) because the weighted average share count rose from 4,389,465 to 13,186,057. |
| Six-month operating cash use | $12.8M | The cleanest burn reference on the page, and the number the $28.4M cash balance has to cover. |
| Q2 R&D expense | $1.5M, down 44.9% year over year | Research spending is falling because the lead program sits between a filed application and a resubmission rather than in the clinic. |
| Q2 SG&A expense | $3.9M, up 101.5% year over year | The doubling reflects launch preparation, market access and commercial build-out that continue while approval is not in hand. |
| Total current liabilities | $8.6M at June 30, 2026, including a $5.1M current Avondale note | Lower than $10.3M at December 31, 2025, but the whole note now sits in current liabilities because the monthly redemptions are outside the company’s control. |
| Accumulated deficit | $147.6M | The cumulative cost of reaching a filed but still unapproved application. |
| Management runway statement | Into mid 2027 | Narrower than the earlier “into 2027” wording, and stated to include the requested CMC work, the approval effort and the commercial build-out for CTx-1301 if approved. |
| Going-concern conclusion | Substantial doubt retained | The filing states that the uncertainties raise substantial doubt about the ability to continue as a going concern for one year after the issuance date of the financial statements; Note 1 reaches the same conclusion. |
| Contracted CDMO spend | Approximately $8.6M | Roughly $1.6M of Bend Bioscience CMC work including verification batches, plus roughly $7.0M for process validation batches. Contract estimates are not a disclosure that the entire amount remains unpaid or must all be paid before filing. |
The balance-sheet improvement came from financing, not operations. Six-month financing cash flow was $30.4 million while operations consumed $12.8 million, moving cash from $11.0 million at the start of the year to $28.4 million at June 30, 2026. Cingulate remains pre-revenue and cannot fund itself until an approved product is launched, reimbursed and sold at sufficient scale.
The forward read has narrowed to two questions. The first is whether SG&A, which doubled year over year while research spending fell 44.9%, is rephased now that the CRL has pushed a launch out. The second is how the roughly $8.6 million of contracted Bend Bioscience manufacturing work is funded, because it is contracted manufacturing work associated with the programme and resubmission the company has not dated. Both sit next to the going-concern language, which the filing retained even with $28.4 million of cash on the balance sheet.
The share count has roughly doubled in a little over seven months. Cingulate had 7,250,299 common shares outstanding at December 31, 2025, 11,908,316 at March 31, 2026 and 13,894,882 at June 30, 2026. The cover of the Q2 Form 10-Q reports 14,541,826 shares outstanding as of August 12, 2026, an increase of 100.6% against the year-end figure. The 13,469,036 shares reported in the May 2026 proxy statement as of May 18, 2026 are a historical waypoint in that sequence, not the current count, and none of these figures include potential future issuance from warrants, options and financing facilities.
Two facilities did most of the work in the quarter. Under the A.G.P. at-the-market programme entered into on March 24, 2026, with capacity of up to $100,000,000 gross and a 3% commission, Cingulate sold 806,893 shares during the second quarter for net proceeds of $4,347,364 after $136,364 of A.G.P. compensation and administrative fees; the six-month totals were 809,593 shares for $4,364,909 net. Under the Lincoln Park purchase agreement of July 21, 2025, which allows up to $25.0 million over a 36-month term, the company sold 1,032,372 shares in the quarter for net proceeds of $5,058,975, and 2,644,178 shares across the six months for $14,065,761 net. The earlier H.C. Wainwright 2023 at-the-market programme, for up to $31.9 million, was terminated effective March 23, 2026 after 210,158 shares had been sold in the six months for net proceeds of $1,304,011. The company’s Q2 release aggregates the at-the-market and Lincoln Park activity as approximately $19.0 million of capital raised in the first half, against $12.8 million of cash used for operations. The 10-Q does not disclose how much capacity remains under either the A.G.P. programme or the Lincoln Park agreement, so the remaining headroom cannot be read from the filing.
The February 2026 private placement included 2,147,472 common shares, 954 Series A convertible preferred shares with a $1,000 stated value and a 12% dividend that auto-converted into 191,824 common shares on March 24, 2026 at $5.04, and warrants for 1,869,415 shares at a $5.04 exercise price, for gross proceeds of approximately $12.0 million. Those warrants are the live overhang. Total warrants outstanding at June 30, 2026 were 2,620,963, of which the 1,869,415 February tranche is by far the largest, and none of them had been exercised through June 30, 2026. The remaining tranches are small: 354,167 June 2024 Series C and 177,083 June 2024 Series D warrants at $7.02, 135,417 February 2024 public-offering warrants at $24.00, 21,250 July 2024 placement-agent warrants at $8.78 and 28,855 September 2023 Series A warrants at $13.56, plus legacy 2021 and 2023 tranches struck at $1,440.00, $1,800.00, $172.80 and $30.00 that are far out of the money. Potentially dilutive securities excluded from the earnings-per-share calculation, covering stock options and common stock purchase warrants, totalled 3,784,266 at June 30, 2026 against 1,232,523 a year earlier. The placement’s 180-day lock-up and its 24-month standstill capped at 40% as converted reduced immediate supply from those investors; they did not remove the shares or warrants from the capital structure.
After June 30, the company sold 220,476 shares to Lincoln Park for $1,068,525 net and 271,717 shares through A.G.P. for $1,394,179 net. Separately, Avondale exchanges extinguished $1,320,000 of principal using 139,751 shares and $600,000 cash in total. The 139,751 shares comprise 67,924 issued July 7 and 71,827 issued August 10; these are components of the total, not additional issuance beyond it.
Cash runway and dilution are two sides of the same equation, and the second quarter moved both at once: cash rose to $28.4 million while the share count rose to 14,541,826 on the August 12, 2026 cover, roughly double the December 31, 2025 level. A stronger share price and a dated resubmission could let Cingulate finance on better terms; a long delay or weak market could require more shares for each dollar raised, with 2,620,963 warrants outstanding and 3,784,266 potentially dilutive securities already excluded from the loss-per-share calculation. The correct question is not only “does the company have cash?” but “how much per-share value remains after the capital needed to reach approval and launch?”
Falcon Creek Capital Advisor was the only holder above 5% listed in the May proxy, with 3,856,766 shares beneficially owned, or 25.91% under the filing’s calculation. The position includes securities purchased through the February private placement on behalf of managed funds. Falcon Creek also received board-designation rights tied to ownership thresholds. This creates a more concentrated strategic shareholder than Cingulate had before the financing, but it also gives one capital provider meaningful influence.
Directors and executive officers as a group beneficially owned 739,628 shares, or 5.30%, using the proxy’s SEC methodology and including certain exercisable options or warrants. Several officers, directors and affiliates participated in the February financing. That is a constructive alignment signal, although insider participation does not eliminate regulatory or dilution risk. Both the 25.91% and the 5.30% figures come from the May 2026 proxy and have been diluted by subsequent issuance, since shares outstanding have risen from 13,469,036 on May 18, 2026 to 14,541,826 on August 12, 2026.
Governance requires a more cautious reading. Shane Schaffer’s 2025 administrative leave and later reinstatement were disruptive at a sensitive stage. In July 2026, the board was reduced to five directors, Schaffer became chairman, Jeff Hargroves became lead independent director, and committee leadership was reorganized. Investors should monitor whether the smaller board maintains sufficient independent challenge while the company manages a high-stakes regulatory and financing process.
The July option awards included both time-based and FDA-approval-contingent components. Performance alignment is positive in principle. The size of the equity plan and recurring share grants still carry a per-share cost. Both statements can be true.
CING attracts retail attention because it combines a small market capitalization, a recognizable FDA narrative, a large-addressable-market story and a relatively low nominal share price. The result is headline sensitivity. “No safety or efficacy concerns” supports a fast-fix narrative; “FDA rejection” and “manufacturing issue” support the opposite narrative. Both can drive sharp moves before new evidence appears.
Social-media discussion on Stocktwits, Reddit and X should be treated as sentiment, not due diligence. Retail commentary can reveal which catalyst is being priced and where expectations are crowded. It cannot verify the content of a confidential CRL, the status of validation work or the FDA’s future classification. Volume, borrow conditions and float concentration can amplify reactions in either direction.
The block below is a snapshot of the Stocktwits flow, with its date. These are opinions of retail traders and non-professional investors, not analyst research, and they measure attention and how one-sided positioning has become rather than anything about the business.
The Stocktwits normalised community sentiment score, on a 0 to 100 scale, by reading date. This is a different metric from the bullish share of messages shown above and the two series should not be compared. The last column is the most recent reading.
These readings come from retail traders and non-professional investors, not analyst research. The score is Stocktwits’ own normalised 0 to 100 summary of that conversation, so it describes the audience rather than the company.
Source: Stocktwits normalised sentiment score series for $CING, read on August 13, 2026.
Merlintrader / the author previously held a small position in Cingulate. The position was sold on June 29, 2026 at $5.21 for a small gain. The author did not hold a CING position at the time of the September 6, 2026 disclosure; this is a historical position statement. This disclosure is provided for transparency and does not constitute a recommendation to buy, sell or hold the security.
Financial data refer to June 30, 2026 unless stated otherwise. Current market and retail-sentiment snapshots were read September 30; historical filing and ownership figures retain their own dates. Editorial review was October 4, 2026. Clinical results, company forecasts and illustrative interpretations are distinguished throughout.
September 17 company update · August 11 pharmacokinetic publication announcement
No. The FDA completed the original review cycle with a Complete Response Letter. CTx-1301 cannot be marketed unless Cingulate addresses the deficiencies and later receives an approval letter.
Not according to Cingulate’s June 2 SEC filing and press release. The company said the identified requests were CMC-related and no current clinical safety or efficacy concern was raised. The full CRL is not public, so this remains the company’s disclosed characterization.
No exact public resubmission date had been confirmed as of September 30, 2026. The Form 10-Q filed on August 13, 2026 says Cingulate intends to resubmit as promptly as practicable and adds that there can be no assurance regarding the timing of any resubmission, that any resubmission will be accepted by the FDA, or that approval will occur at all. Investors should wait for a formal announcement that the complete response has been filed.
It independently reviewed and publicly detailed the 103-patient pediatric fixed-dose study. The 25-mg and 37.5-mg groups met the prespecified p<0.017 threshold for the primary ADHD-RS-5 endpoint; the 18.75-mg group narrowly missed at p=0.018. No serious TEAEs or new safety signals were reported. Because the trial enrolled 103 of 385 planned participants, the authors described the findings as preliminary and said larger confirmation is needed.
Yes, it is a plausible scenario, and July option awards include approval-in-2027 conditions. It is not guaranteed. Timing depends on completion of the CMC work, the filing date, FDA classification, inspection needs and the absence of new deficiencies.
It determines the expected length of the FDA review after a complete resubmission. A shorter Class 1 goal would reduce time and cash burn; a Class 2 review generally means a longer six-month goal and greater financing exposure.
No. Patent protection can preserve exclusivity and improve future product economics, but it does not establish safety, efficacy, manufacturing compliance or permission to market the drug.
Every Merlintrader stock hub, catalyst update and market brief is published to Telegram the moment it goes live. No paywall, no spam, just the research.
Disclaimer. This content is published by Merlintrader for educational and informational purposes only. It is independent market analysis. It does not constitute investment advice, an investment recommendation, an offer or a solicitation to buy or sell any security, Nothing here should be read as a recommendation to buy, sell or hold $CING or any other security.
Figures are taken from public filings with the U.S. Securities and Exchange Commission, company press releases and market-data providers, and are stated with their reference dates. Data can change without notice, and figures published before a results release become outdated the moment that release is issued. Merlintrader makes no representation that the information is complete or current at the time of reading. Readers should verify every figure against the primary source before acting on it.
Biotechnology and healthcare companies carry binary risk. Clinical trials fail, regulatory decisions go against the applicant, approval does not guarantee commercial uptake, and development-stage companies frequently raise equity at whatever price the market will bear. A single readout can change the value of the business overnight in either direction, and companies at this stage can lose all of their value. Every reader is responsible for their own decisions and should consult a licensed financial adviser where appropriate.
Merlintrader may hold positions in securities mentioned. Some links on this page are affiliate or referral links, including those to Finviz and Stocktwits, which may generate a commission at no cost to the reader. Full legal information is available on the disclaimer and terms of use and privacy pages.